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Solving manufacturing problems for L-carnitine-L-tartrate 
to improve the likelihood of successful product scale-up
L-carnitine-L-tartrate, a non-essential amino acid, is hygro-
scopic. This causes a problem in tablet production due to 
pronounced adhesion of tablets to punches. A 33 full facto-
rial design was adopted to suggest a tablet formulation. 
Three adsorbents were suggested (Aerosil 200, Aerosil 
R972, talc) to reduce stickiness at three concentrations (1, 3 
and 5 %), and three fillers (mannitol, Avicel PH 101, Dibasic 
calcium phosphate) were chosen to prepare 27 formula-
tions. Micromeritic properties of formulations were stud-
ied, and tablets were prepared by wet granulation. Absence 
of picking, sticking or capping, recording of sufficient 
hardness, acceptable friability and tablet ejection force in-
dicated formulation success. The resulting formulation 
prepared using Avicel PH 101 and 1 % Aerosil 200 was sub-
mitted to further investigation in order to choose the most 
suitable compression conditions using a 33 full factorial de-
sign. Variables included compression force, tableting rate 
and magnesium stearate (lubricant) concentration. The for-
mulation prepared at compression force of 25 kN, using 2 % 
magnesium stearate, at a production rate of 30 tablets/ min-
ute, was found to be the most appropriate scale up candi-
date.
Keywords: L-carnitine-L-tartrate, adsorbent, scale-up, com-
pression force, ejection force, hygroscopic
Carnitine is a non-essential amino acid derivative and a cofactor of fatty acid metabo-
lism in the heart, liver and skeletal muscle (1). It was designated vitamin Bt but is not an of-
ficially recognized vitamin (2). It is found primarily in animal products such as meat (prin-
cipally red meat), fish, poultry (2). In humans, the liver, brain and kidney synthesize carnitine 
(3, 4). Carnitine is an endogenous mitochondrial membrane compound (5) and its deficiency 
results in disordered membrane transport (1, 2). L-carnitine is a ((R)-(3-carboxy-2-hydroxy-
propyl) trimethylammonium hydroxide inner salt) (6). It occurs in two distinct stereoiso-
mers, namely, L-carnitine (naturally occurring carnitine, which is biologically active) and 
D-carnitine (synthetic carnitine, which is biologically inactive) (7). L-carnitine is a white or 
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almost white crystalline powder or comes in the form of colorless crystals, hygroscopic and 
freely soluble in water. It is soluble in warm ethanol (96 %) and practically insoluble in ace-
tone, ether and benzene (8, 9). L-carnitine was formulated easily into liquid preparations 
such as an oral solution and i.v. injection. Due to its hygroscopicity, its formulation into cap-
sules is not preferred (10), as the stability of the capsule shell is affected (11).
Formulation of L-carnitine-L-tartrate into tablets offers many advantages over hard 
gelatin capsules. Tablets can contain a relatively high dose of L-carnitine-L-tartrate, main-
ly 485.3 mg, which is equivalent to 330 mg of L-carnitine base. Also, tablets enable the use 
of many excipients in quantities sufficient to overcome the adverse effects of L-carnitine- 
L-tartrate hygroscopicity on tablet properties.
Many problems are expected during the formulation of L-carnitine-L-tartrate into 
tablets, including the occurrence of picking/sticking and high ejection forces during com-
pression due to its hygroscopic nature. The stronger the ejection force, the greater is the 
need for a lubricant in the formulation (10, 12). Ejection force can be taken as a measure for 
the effectiveness of lubrication and decrease of propensity for material punch sticking (10). 
Ejection forces below 200 N are optimal, although forces up to 400 N are commonly em-
ployed. Ejection forces ranging between 400 and 800 N are considered to be high (10) since 
they cause tablet tooling damage and can introduce cracks into tablet structure. Increasing 
the percentage of lubricant in the formulation can, however, reduce the dissolution rate 
and hence affect the bioavailability of the drug. A proper amount of lubricant should, 
therefore, be chosen (10). Thus, sufficient tablet lubrication is required to lower the tablet 
ejection force without retarding drug release from the tablet (13).
During the scale-up process, increasing the speed of the tablet press results in in-
creased tendency of the tablet to cap (10). Thus, increasing the speed of tablet compression 
can result in reduced tablet hardness (14).
The die fill and applied compression force influence tablet hardness and thickness. At 
a constant die fill, the greater the compression force, the higher is the tablet hardness and 
the lower its thickness. Higher die fill at constant compression forces leads to higher tablet 
hardness (12).
Compressibility and ejection profiles as well as dissolution and disintegration time 
profiles related to the range of compression forces are unique for each formulation. Com-
pactibility and ejection profiles can be used to evaluate the influence of excipients and 
lubricants (10).
In this study, L-carnitine-L-tartrate was formulated into tablets with different excipi-
ents. The effect of tablet filler, type and level of adsorbents on tablet hardness and ejection 
force was studied. Tested excipients had the advantages of abundance and cost efficiency. 
Out of the tested, the best tablet formulation was selected to study the effect of compres-
sion force, tablet press speed and lubricant level on tablet hardness and ejection force, in 
order to suggest the best conditions for formulation scale-up.
EXPERIMENTAL
Materials
L-carnitine-L-tartrate (Kaiyuan Hengtai Chemical Co. Ltd., China), mannitol (Shan-
dong Bangye Co. Ltd., China), dibasic calcium phosphate (DCP) (El-Nasr Chemicals, 
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Preparation of L-carnitine-L-tartrate tablets using wet granulation
Tablets of L-carnitine-L-tartrate were prepared by the wet granulation technique us-
ing a number of excipients. Success of the formulation to reduce the drawbacks caused by 
hygroscopicity of L-carnitine-L-tartrate is evidenced by the absence of picking and stick-
ing during tablet compression. A full factorial design was constructed for the wet granula-
tion formulations according to Table I. Effects of the type of filler (X1), type of adsorbent 
(X2) and the concentration of adsorbent (X3) on tablet hardness and tablet ejection force 
(independent variables) were studied.
Three different tablet fillers were selected to study their effect on tablet properties, 
namely, mannitol, dibasic calcium phosphate and microcrystalline cellulose Avicel PH 101. 
Fig. 1. Flow chart summarizing the plan of the study.
Egypt), microcrystalline cellulose Avicel PH 101 (FMC biopolymer, Ireland), colloidal sili-
con dioxide Aerosil 200 and hydrophobic colloidal silica Aerosil R972 (Evonik Degussa, 
Germany), Talc (Golcha, India), Polyvinyl-pyrrolidone 30 K Povidone K30 (Fluka, USA), 
croscarmellose sodium Ac-Di-Sol (FMC biopolymer) and magnesium stearate (Peter 
Greven, Malaysia).
The study can be summarized in the following Fig. 1.
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Table I. The 33 full factorial design for the L-carnitine tablet formulation
Formulation X1 (filler type) X2 X3 (adsorbent conc.)
A1 –1 –1 –1
A2 0 –1 –1
A3 1 –1 –1
A4 –1 0 –1
A5 0 0 –1
A6 1 0 –1
A7 –1 1 –1
A8 0 1 –1
A9 1 1 –1
A10 –1 –1 0
A11 0 –1 0
A12 1 –1 0
A13 –1 0 0
A14 0 0 0
A15 1 0 0
A16 –1 1 0
A17 0 1 0
A18 1 1 0
A19 –1 –1 1
A20 0 –1 1
A21 1 –1 1
A22 –1 0 1
A23 0 0 1
A24 1 0 1
A25 –1 1 1




Independent variables Low Medium High
X1 = filler type Mannitol DCPa Avicel PH 101
X2 = adsorbent type Aerosil 200 Aerosil R972 Talc
X3 = adsorbent conc. 1 % 3 % 5 %
Transformed values –1 0 1
a Dibasic calcium phosphate 
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Three different adsorbents, namely, colloidal silicon dioxide Aerosil 200 and hydrophobic 
colloidal silica Aerosil R972 as well as talc, were used at three different levels (1, 3 and 5 %). 
Polyvinyl-pyrrolidone 30 K (Povidone K30) was chosen as binder at 5 %, croscarmellose 
sodium (Ac-Di-Sol) was used as disintegrant at 5 % (m/m) (15), and magnesium stearate was 
chosen as lubricant at 1 % (m/m).
The amount of 485.3 mg L-carnitine-L-tartrate, equivalent to 330 mg L-carnitine, rep-
resented the tablet dose (16).
Evaluation of suggested formulations
Suggested formulations were evaluated through the study of their micromeritic bulk 
properties, including the powder flow rate, angle of repose, bulk and tapped density, 
Carr’s index and Hausner‘s ratio (17). Micromeritic bulk properties of the suggested for-
mulations were compared with those of L-carnitine-L-tartrate.
Preparation of tablets
Tablets were prepared from the suggested formulations, using wet granulation. L-
carnitine-L-tartrate, the filler, the adsorbent and Ac-Di-Sol were passed through a sieve of 
710 µm where geometric dilution was carried out by mixing powders in a Turbula Shaker 
Mixer (Germany) for 10 minutes. Povidone K30 was dissolved in 3 times its mass isopro-
panol (i.e., 25 % (m/m) and was added gradually to the former powder mixture in a double-
Z kneader; granulation proceeded for 15 minutes with the addition of isopropanol until a 
coherent mass was obtained and wet granules were passed through a 2000 µm sieve. Wet 
sieving was followed by drying the granules in an oven (Drying Oven WOF-155, Daihan 
Scientific, Korea) at 50 °C until moisture content dropped to 2–3 %. Dried granules were 
then passed through a 850 µm sieve. Magnesium stearate was passed through a 180 µm 
sieve, added to the granules and mixed well for 2 minutes just before compression. Admix-
ing of lubricant was followed by compression into tablets, using the oblong 20 × 9 mm 
punch on a single punch tablet press (Korsch XP 1).
Formulations were prepared in batches of at least 300 tablets. The tablet press was 
automatically run at a rate of 10 tablets/minute, at upper and lower punch pressures of 25 
kN. Tablet final mass was about 1 g. Ejection force values were recorded during the opera-
tion. Upper and lower punches were photographed at the end of compression of each 
formulation to check the occurrence of picking or sticking.
Evaluation of prepared tablets
The prepared tablet formulations were evaluated through determination of the drug 
content, uniformity of dosage units (9), tablet hardness (12), tablet friability, tablet thick-
ness, disintegration time (17) and dissolution rate (9).
The best formulation was selected with regard to the absence of formulation picking 
and sticking to dies and punches. Selection of the best formulation was based on the evalu-
a tion of tablet hardness and friability, followed by ejection force. Formulations were evalu-
ated also regarding their disintegration time, drug content and percentage of drug dis-
solved. The latter tests, though important in formulation evaluation, had lesser impact in 
formulation selection.
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Table II. The 33 full factorial design for the choice of best compression parameters for the L-carnitine-L-tar-
trate tablet formulation





B1 –1 –1 –1
B2 0 –1 –1
B3 1 –1 –1
B4 –1 0 –1
B5 0 0 –1
B6 +1 0 –1
B7 –1 +1 –1
B8 0 +1 –1
B9 +1 +1 –1
B10 –1 –1 0
B11 0 –1 0
B12 +1 –1 0
B13 –1 0 0
B14 0 0 0
B15 +1 0 0
B16 –1 +1 0
B17 0 +1 0
B18 +1 +1 0
B19 –1 –1 +1
B20 0 –1 +1
B21 +1 –1 +1
B22 –1 0 +1
B23 0 0 +1
B24 +1 0 +1
B25 –1 +1 +1
B26 0 +1 +1
B27 +1 +1 +1
Levels
Independent variables Low Medium High
X1 = compression rate 15 tab/min 30 tab/min 45 tab/min
X2 = compression force 5 kN 15 kN 25 kN
X3 = lubricant conc. 0.5 % 1 % 2 %
Transformed values –1 0 +1
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Formulation failure was based on sticking of tablets to the punches, a result of drug 
hygroscopicity, where failed formulations were rejected.
Determination of the best compression parameters for L-carnitine-L-tartrate formulation
The best formulation was subjected to different compression parameters and lubri-
cant concentrations in order to single out the formulation with sufficient potential for 
transfer to a larger scale. A 33 full factorial design was adopted to study the effect of two 
compression parameters and lubricant concentrations on tablet properties (Table II). The 
effect of the compression rate (X1), compression force (X2) and lubricant concentration (X3) 
on tablet ejection force and tablet hardness was studied. These parameters represented 
independent variables.
The tablets prepared under most favorable conditions were evaluated as indicated 
previously.
RESULTS AND DISCUSSION
Table III summarizes the bulk micromeritic properties of L-carnitine-L-tartrate pow-
der and its granulated formulations (all formulations contained 1 % magnesium stearate 
as lubricant), designated A1 through A27.
Previous results showed appropriate flow for L-carnitine-L-tartrate; however, such 
flow was impaired with time due to L-carnitine-L-tartrate hygroscopicity. It was evident 
that bulk micromeritic properties were strongly influenced by the type of excipients used. 
Change of filler type affected the flow rate significantly (p = 0.0404). Bulk and tapped den-
sities of each formulation were influenced by filler types (p = 0.0139 for bulk density; p = 
0.0069 for tapped density at p < 0.05). This was attributed to the relatively high percent of 
these fillers in the formula (35–40 %, m/m). Due to the low concentration of the adsorbents 
used (1, 3 and 5 %, m/m), bulk and tapped densities of the formulations were not affected 
(p = 0.458 at p < 0.05) by adsorbents used or even their concentrations. Statistical analysis 
was performed with ANOVA, using the computer program SPSS Version 20.
The effect of changing the adsorbent type or adsorbent concentration on the flow rate 
of powder was minor compared to that of the filler type. Results for the angle of repose, 
which ranged from 26.1 to 33.7°, signified that the flowability of all formulations ranged 
from good to excellent flow.
The results of Carr’s index and Hausner ratio showed that changing the filler type had 
a stronger impact on powder flowability rather than changing the adsorbent type or ad-
sorbent concentration. Formulations containing dibasic calcium phosphate possessed 
good to excellent flowability, while those containing mannitol and Avicel PH101 possessed 
fair flowability.
Fig. 2 shows photographs of upper and lower punches of the tablet press at the end of 
the compression process of each formulation. They revealed occurrence of sticking for 
formulations with low concentrations of Aerosil 200 and Aerosil R972. Sticking occurrence 
decreased as the percentage of adsorbent increased. As for talc, sticking was observed at 
all its concentrations in formulations containing mannitol and dibasic calcium phosphate. 
Nevertheless, no sticking was observed at all with Avicel PH101 with any of the adsorbents 
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Table III. Micromeritic properties of L-carnitine-L-tartarate and its granulated formulations
No. Flow rate
(cm3 s–1)
Bulk density  
(g cm–3)




A1 14.87 ± 1.86 0.554 ± 0.019 0.684 ± 0.025 673.90 ± 25.47
A2 16.71 ± 0.019 0.781 ± 0.019 0.863 ± 0.017 545.07 ± 10.76
A3 14.36 ± 0.014 0.452 ± 0.014 0.549 ± 0.025 505.20 ± 11.54
A4 13.25 ± 1.86 0.591 ± 0.019 0.694 ± 0.025 850.67 ± 48.08
A5 12.48 ± 0.019 0.749 ± 0.019 0.824 ± 0.017 533.00 ± 11.64
A6 14.89 ± 0.014 0.456 ± 0.014 0.529 ± 0.025 607.33 ± 18.88
A7 11.50 ± 1.86 0.554 ± 0.019 0.652 ± 0.025 694.17 ± 77.01
A8 14.11 ± 0.019 0.728 ± 0.019 0.819 ± 0.017 569.93 ± 37.19
A9 13.04 ± 0.014 0.470 ± 0.014 0.573 ± 0.025 535.37 ± 26.88
A10 12.46 ± 1.86 0.573 ± 0.019 0.690 ± 0.025 971.70 ± 87.21 
A11 13.05 ± 0.019 0.737 ± 0.019 0.829 ± 0.017 447.30 ± 15.22
A12 13.01 ± 0.014 0.462 ± 0.014 0.532 ± 0.025 623.60 ± 30.96
A13 10.56 ± 1.86 0.591 ± 0.019 0.711 ± 0.025 752.37 ± 21.36
A14 15.89 ± 0.019 0.764 ± 0.019 0.852 ± 0.017 436.53 ± 31.81
A15 15.48 ± 0.014 0.462 ± 0.014 0.558 ± 0.025 695.77 ± 24.68
A16 11.37 ± 1.86 0.555 ± 0.019 0.639 ± 0.025 610.90 ± 38.62
A17 15.91 ± 0.019 0.743 ± 0.019 0.846 ± 0.017 567.87 ± 57.16
A18 15.91 ± 0.014 0.460 ± 0.014 0.555 ± 0.025 494.17 ± 33.76
A19 13.07 ± 1.86 0.592 ± 0.019 0.682 ± 0.025 1215.07 ± 145.22
A20 11.86 ± 0.019 0.721 ± 0.019 0.830 ± 0.017 636.10 ± 19.54
A21 11.09 ± 0.014 0.467 ± 0.014 0.526 ± 0.025 611.43 ± 26.44
A22 13.63 ± 1.86 0.603 ± 0.019 0.700 ± 0.025 1532.43 ± 57.42
A23 13.23 ± 0.019 0.727 ± 0.019 0.824 ± 0.017 593.87 ± 31.90
A24 12.32 ± 0.014 0.500 ± 0.014 0.600 ± 0.025 675.80 ± 105.15
A25 14.31 ± 1.86 0.575 ± 0.019 0.649 ± 0.025 777.00 ± 89.59
A26 16.51 ± 0.019 0.734 ± 0.019 0.860 ± 0.017 537.87 ± 11.03
A27 11.58 ± 0.014 0.455 ± 0.014 0.526 ± 0.025 542.57 ± 43.65
at their three concentrations. This was attributed to the fact that Avicel PH 101 also acted 
as adsorbent at concentrations of 20–90 % (15). Avicel PH 101 comprised about 50 % of the 
tablet mass, which made the adsorption capacity of Avicel PH 101 exceed that of the three 
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Fig. 2. Photograph of upper and lower punches after compression of L-carnitine-L-tartrate tablet 
formulations with formulations that showed sticking.
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adsorbents at comparatively low concentrations. It was thus possible to conclude that Avi-
cel PH 101 formulations were strong candidates for further investigation.
The adsorbing capacity of Aerosil 200 and Aerosil R972 was far better than that of talc, 
and increased by raising their concentrations (15). This was also due to the fact that Aero-
sil has very small particles joined in larger aggregates (19). Hence, formulations containing 
Aerosils possessed superior properties compared to talc containing formulations.
Ejection force
Statistical analysis of the ejection force results using ANOVA showed that all the fac-
tors had a significant effect on the ejection force. The effects could be ranked in descending 
order as follows: filler type > adsorbent concentration > adsorbent type. This was explained 
by the fact that the filler in these formulations comprised about 35–40 % of tablet mass vs. 
1–5 % of tablet mass corresponding to adsorbent concentration.
Dibasic calcium phosphate formulations possessed the lowest ejection forces (540.8 ± 
67.3 N), followed by Avicel PH-101 (587.9 ± 81.1 N), while those containing mannitol exhibi-
ted the highest values (897.6 ± 293.0 N). The relatively lower ejection forces associated with 
dibasic calcium phosphate were attributed to good flow properties of its formulations, 
which meant reduced adhesion to die walls. Consequently, lower ejection forces were re-
quired. Avicel PH101 possessed some lubricant properties (15), thus helping to eject the 
tablets from the die. Mannitol, being a cohesive powder, was associated with high ejection 
forces, although the recommended levels of magnesium stearate (1–2 %, m/m) were used.
As for the effect of adsorbent type on ejection force, talc showed the most uniform 
ejection forces, for it adsorbed humidity and minimized adherence to die walls and, hence, 
augmented magnesium stearate in tablet lubrication during the compression process (15).
A significant interaction occurred between filler type and adsorbent concentration 
(regardless of the adsorbent type). It was clear that as the concentration of adsorbent in-
creased, the ejection force value increased as well. Formulations containing Aerosil 200 or 
Aerosil R972 as adsorbent showed higher ejection forces than talc with increasing their 
concentration. This resulted from the fact that colloidal silica reduced the efficiency of lu-
brication brought about by addition of magnesium stearate (20).
Significant interaction took place between the adsorbent type and its concentration. It 
was clear for Aerosil 200 and Aerosil R972 that as their percentage increased, the ejection 
force increased as well. Talc concentrations, however, did not affect the ejection force sig-
nificantly (p < 0.05).
The results of evaluation tests performed on the different tablet formulations are list-
ed in Table IV.
Tablet hardness
Statistical analysis of hardness results showed that all studied factors had a significant 
effect on tablet hardness in the following order: filler type > adsorbent concentration > 
adsorbent type. The highest values of tablet hardness were recorded for Avicel PH101 
(151.66 ± 1.08 N for A27 up to 270.4 ± 0.59 N for A3) compared to other fillers. Formulations 
containing DCP showed hardness ranging from 79.26 ± 1.21 N (A14) to 148.03 ± 0.78N (A8). 
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A1 98.69 ± 0.82 80.24 ± 0.46 5.82 ± 0.05 126.45 ± 0.61 0.38 % 5.5
A2 102.99 ± 0.40 81.31 ± 0.68 4.97 ± 0.06 124.19 ± 0.73 friable 5
A3 100.71 ± 0.96 88.25 ± 0.55 5.79 ± 0.03 270.36 ± 0.59 0.00 % 9.5
A4 93.65 ± 0.68 94.51 ± 0.59 5.79 ± 0.04 159.51 ± 2.34 0.28 % 7.25
A5 93.70 ± 1.25 82.76 ± 0.80 4.98 ± 0.02 111.83 ± 1.19 0.30 % 6
A6 97.58 ± 0.48 91.46 ± 0.70 5.88 ± 0.03 225.83 ± 1.83 0.00 % 9
A7 105.62 ± 0.43 90.74 ± 0.82 5.79 ± 0.05 150.88 ± 0.72 0.20 % 6.75
A8 107.73 ± 0.20 97.07 ± 0.80 5.00 ± 0.04 148.03 ± 0.78 0.10 % 4.75
A9 99.81 ± 0.74 90.19 ± 0.85 5.87 ± 0.05 192.37 ± 2.81 0.00 % 8.5
A10 105.04 ± 0.65 84.39 ± 1.03 5.85 ± 0.02 135.87 ± 1.01 0.36 % 6.5
A11 102.35 ± 0.38 78.37 ± 0.48 5.11 ± 0.06 96.73 ± 0.48 friable 4.5
A12 100.87 ± 1.22 100.10 ± 0.99 5.89 ± 0.1 254.78 ± 2.63 0.00 % 8.5
A13 102.59 ± 0.67 82.95 ± 0.62 5.84 ± 0.05 108.6 ± 1.63 0.38 % 6.25
A14 106.74 ± 0.43 99.19 ± 0.79 5.14 ± 0.11 79.26 ± 1.21 friable 4
A15 106.05 ± 0.67 101.49 ± 0.78 5.95 ± 0.07 199.54 ± 1.8 0.00 % 8
A16 101.78 ± 0.67 88.23 ± 0.96 5.71 ± 0.05 133.12 ± 2.35 0.28 % 5.75
A17 100.55 ± 1.01 69.94 ± 0.51 4.98 ± 0.05 135.57 ± 0.89 0.16 % 5.25
A18 100.14 ± 0.35 80.34 ± 0.98 5.75 ± 0.03 178.44 ± 1.07 0.06 % 10.25
A19 96.90 ± 0.43 82.17 ± 0.94 5.80 ± 0.06 157.94 ± 0.23 0.22 % 6
A20 107.05 ± 0.35 106.48 ± 0.77 5.10 ± 0.06 142.25 ± 1.08 friable 4.25
A21 102.78 ± 0.50 79.75 ± 0.65 5.91 ± 0.06 226.91 ± 1.51 0.02 % 9
A22 104.71 ± 0.29 91.13 ± 0.79 5.95 ± 0.08 112.62 ± 2.23 friable 6
A23 106.59 ± 0.23 101.50 ± 0.82 5.11 ± 0.07 104.48 ± 2.96 friable 5
A24 107.01 ± 0.47 99.94 ± 0.95 5.93 ± 0.13 158.43 ± 2.23 0.04 % 8.5
A25 101.83 ± 0.32 76.31 ± 0.90 5.72 ± 0.07 121.25 ± 1.29 0.18 % 7.5
A26 108.22 ± 1.05 100.50 ± 0.79 4.98 ± 0.02 117.43 ± 1.53 friable 5
A27 101.05 ± 0.77 71.30 ± 0.80 5.75 ± 0.03 151.86 ± 1.08 0.18 % 9
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Formulations containing mannitol showed hardness ranging from 108.6 ± 1.63 N (A13) to 
159.51 ± 2.34 N (A4). This was due to the formation of significant hydrogen bonding be-
tween the particles of cellulose (21). The higher the concentration of the adsorbent, the 
lower was the hardness of the tablet, because of the interference of Aerosil particles with 
those of Avicel, which probably led to the weakening of interparticle interactions, thus 
weakening the tablet. Similarly, increasing the percent of talc resulted in a reduction of 
tablet hardness.
However, both formulations containing dibasic calcium phosphate or mannitol as 
filler showed relatively similar tablet hardness results with different adsorbent concentra-
tions (regardless of the adsorbent type). Dibasic calcium phosphate, upon compaction and 
in situ fragmentation, resulted in clean lubricant free surfaces; hence, its binding properties 
were not affected (22). Similarly, wet granulation of mannitol prior to tablet compression 
improved its binding properties (22). It was also clear from the obtained results that the 
higher the hardness, the lesser was the friability and the longer the disintegration time of 
the tablets.
From the preceding results (Table IV), the tablet formulation with the most overall 
acceptable results was selected regarding tablet hardness, friability and disintegration 
time, taking into consideration that the values of ejection force during compression did not 
exceed acceptable limits (friability less than 1 %, ejection force ranging between 400 and 
600 N and disintegration time less than 15 minutes). Formulations containing talc pos-
sessed uniform ejection forces and, along with Avicel PH 101, showed no sticking. How-
ever, such formulations had a strong drawback, that is, low hardness, which is not encour-
aging for a candidate for scale up. Formulations containing Aerosil, along with Avicel PH 
101, were acceptably hard with no sticking, showing relatively higher ejection forces com-
pared to those containing talc. However, ejection forces were decreased by decreasing the 
Aerosil concentration. Formulation A3, which contained Avicel PH-101 as filler and 1 % of 
Aerosil 200 as adsorbent, was selected for further investigation as it showed the highest 
hardness of 270.36 ± 0.59 N, 0.0 % friability, ejection force of 505.2 ± 11.5 N and disintegra-
tion time of 9.5 minutes. Such results were considered acceptable relative to the results of 
the other formulations.
Choice of the best tablet compression parameters
Formulation A, which had acceptable evaluation results, was chosen to complete the 
studies of compression parameters. Effects of the compression force, compression rate and 
lubricant concentration on tablet hardness and ejection force were traced. The values of 
ejection forces, and the upper punch and lower punch pressures were recorded during the 
compression of tablets in order to select appropriate tableting process parameters and lu-
bricant levels.
Table V gives the tablet hardness and ejection force values for formulations B1 through 
B27. Statistical analysis of ejection force and tablet hardness results revealed that all factors 
had a significant effect on the tablet ejection force (p < 0.0001) and tablet hardness (p < 
0.0001). The effects on both ejection force and tablet hardness could be ranked in descend-
ing order as follows: compression force >> lubricant concentration > compression rate. 
Compression force was the dominant factor for the tableting process and was directly re-
lated to tablet hardness and friability (10).
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Table V. Hardness and ejection force for tablet formulations B1 to B27
Formulation Tablet hardness (N) Ejection force (N)
B1 19.33 ± 0.32 351.86 ± 6.71
B2 19.52 ± 0.28 370.17 ± 8.13
B3 21.88 ± 0.17 387.05 ± 5.94
B4 118.8 ± 0.32 602.81 ± 14.01
B5 123.9 ± 0.59 659.57 ± 11.37
B6 123.9 ± 0.57 661.11 ± 11.64
B7 225.34 ± 0.54 831.96 ± 16.64
B8 245.64 ± 1.17 870.81 ± 15.18
B9 217.78 ± 0.69 849.10 ± 18.95
B10 17.36 ± 0.15 318.42 ± 5.36
B11 13.73 ± 0.17 344.71 ± 6.21
B12 14.52 ± 0.19 383.10 ± 14.30
B13 116.64 ± 0.51 564.89 ± 7.38
B14 111.74 ± 0.84 622.13 ± 14.14
B15 112.13 ± 0.46 657.76 ± 12.12
B16 204.24 ± 0.75 743.91 ± 11.16
B17 183.35 ± 0.53 810.76 ± 19.16
B18 193.94 ± 0.88 845.45 ± 15.88
B19 10.69 ± 0.39 300.86 ± 5.11
B20 8.73 ± 0.62 333.64 ± 6.36
B21 5.49 ± 0.61 352.51 ± 10.10
B22 91.92 ± 0.55 536.53 ± 8.05
B23 95.94 ± 0.42 586.23 ± 9.79
B24 81.72 ± 0.61 617.22 ± 10.39
B25 178.74 ± 0.68 681.45 ± 9.99
B26 177.56 ± 0.58 735.88 ± 11.12
B27 153.13 ± 1.02 780.77 ± 14.77
High compression force and the accompanying elastic deformation, high tableting 
speed and insufficient lubrication increased the tablet die-wall friction, which resulted in 
an increase in its ejection force. These factors should be compromised to achieve acceptable 
product quality without harming the production equipment.
Magnesium stearate, used as lubricant, acted by being adsorbed onto the surface of 
granules and forming a film, thus decreasing the tablet crushing force and ejection force 
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during compression (10). Hence, upon increasing the concentration of magnesium stearate, 
the ejection force of formed tablets was decreased. Addition of lubricant caused a reduc-
tion in tablet breaking strength. As the diluent was mixed with the lubricant, each diluent 
particle became coated with a thin film of lubricant that interfered with interparticulate 
bonding (23). This effect on tablet hardness was observed when lubricant level increased 
from 0.5 to 2 %. Thus, although the use of lubricant was necessary to lower the ejection 
force, it produced defective tablets by lowering tablet hardness. Also, as the punch speed 
increased, the porosity of tablets and their propensity to capping and lamination in-
creased. The tensile strength of compacts tended to decrease with faster speeds, espe-
cially for plastic and viscoelastic materials, such as microcrystalline cellulose. Such com-
pacts had the tendency to cap or laminate at higher speeds (10).
Although tested formulations had optimum ejection forces ranging from 300.9 N (B19) 
to 387.1 N (B3), all trials compressed at 5 kN were rejected because they were friable and 
of very low hardness (not exceeding 29.43 N), which could not be accepted, especially for 
large tablets. Also, although the ejection forces of trials compressed at 15 kN ranged from 
high 536.5 N (B22) to very high 661.1 N (B6), the results of their corresponding tablet hard-
ness were critical, ranging from 81.42 N (B24) to 123.9 N (B5), which would probably be 
even lower in scaling-up, endangering the quality of the product during large scale pro-
duction.
Hence, selection of the most acceptable trial was restricted to formulations com-
pressed at 25 kN. These trials had the highest hardness values ranging from 153.13 N (B27) 
to 245.64 N (B8); still, they had very high (681.5 N for B25) to extremely high ejection forces 
(870.8 N for B8). Thus, the most acceptable trials were B25 (178.74 and 681.5 N) and B26 
(177.56 and 735.9 N). Although trial B25 showed better results than B26, trial B26 was se-
lected to be the most acceptable one because it had the advantage of higher productivity 
(30 tab/min) over B25 (15 tab/min).
CONCLUSIONS
Formulation of the hygroscopic drug L-carnitine-L-tartrate into tablets with minimal 
tableting problems was achieved by using Avicel PH 101 as filler, 1 % Aerosil as adsorbent 
and 2 % magnesium stearate. Tablets, prepared by wet granulation, were compressed at 25 
kN at a production rate of 30 tablets/ min. Such tablet formulation with acceptable hard-
ness, friability and ejection force can be considered to be a candidate for successful scale-
up.
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